J. M. Vauthier

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Sabine Tejpar, Eric Van Cutsem, Érick Gamelin et al. · Journal of Clinical Oncology · 2004 · 30 citations

Medicine, Oncology, Pharmacology +17

A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)

E. Casado, Gunnar Folprecht, L. Paz-Ares et al. · Journal of Clinical Oncology · 2004 · 26 citations

Medicine, Pharmacokinetics, Pharmacology +17

PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: Baseline characteristics and safety evaluation.

Philippe Caillet, Marina Pulido, Étienne Brain et al. · Journal of Clinical Oncology · 2021 · 23 citations

Medicine, Oncology, Pharmacology +14

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Sabine Tejpar, Eric Van Cutsem, Érick Gamelin et al. · Journal of Clinical Oncology · 2004 · 11 citations

Medicine, Oncology, Pharmacology +17